Tehran – A Trilateral Memorandum (MOU) has been signed to promote the country’s position in the plasma medical industry regarding the importance of integrating new technologies into healthcare systems.
The MOU was signed by Saeed Sarkar, a Vice President of Science and Technology, Shahin Akhoundzadeh, a Ministry of Health official, and Mahdiyeh Bakhtiari, CEO of the Plasma Therapy Knowledge Base company, the IRNA reported.
The main objective of the MOU is to develop and carry out a wide range of multicenter research in plasma medicine, integrate technology into national formal treatment protocols, implement projects that play an effective role in the treatment of difficult-to-treat diseases, improve health services, and provide access to advanced medical technologies.
The MOU represents the cooperation of the country’s science, research and technical capabilities. This is a national movement aimed at expanding emerging technologies in the field of medicine.
First Indigenous Plasma Therapy Clinic
In April, Iran’s Atomic Energy Organization (AEOI) collaborated with Jahrom Medical Sciences University in Southern Fars to launch its first cold plasma therapy clinic for the treatment of wounds using Indigenous technology.
At the opening ceremony, AEOI Head Mohammad Eslami linked the outcomes to scientific advancement and national confidence, highlighting the use of nuclear technology in health services and agriculture.
The clinic’s inauguration ceremony could help other medical centers across the country expand plasma therapy technology, officials noted.
Hossein Hakimerahi’s Prime Minister of Jafflom University of Medical Sciences has expressed his hope that the initiative will open up opportunities for the use of nuclear technology in cancer treatment and other health areas.
On August 26, Eslami said heavy water derivatives and plasma medicine are opening new frontiers in drug development and medicine, marking major steps in the application of nuclear technology to public health.
Eslami added that under the Ministry of Health Memorandum, clinical trials previously concentrated at Tehran University will be expanded to selected universities across the country.
“This will accelerate the spread of plasma-based technologies to various states,” he said.
The remarks were made at a ceremony marking National Doctor’s Day. There, Eslami also emphasizes the success of AEOI in producing more than 70 types of radiopharmaceuticals, and is now supplied to more than 220 nuclear medicine centres in Iran and exported overseas.
According to Eslami, these products cover three categories: diagnosis, treatment and palliation.
In the field of diagnostics, advances are pushing forward the “frontier of knowledge” and improving accuracy so that doctors can better examine the patient’s body. On the treatment side, he added, the focus is on alleviating the suffering of patients while providing more effective treatment.
Eslami reveals that around 20 additional radiopharmaceuticals are currently in the research and clinical trial stages, reflecting Iran’s growth ability to integrate nuclear science into medicine.
mt/mg